Related Experiment Video
Updated: Aug 9, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Dementia with Lewy bodies: an emerging disease
1Via Christi Family Medicine Residency, Wichita, Kansas 67218, USA. Doug_Neef@via-christi.org
American Family Physician
|April 21, 2006
Summary
Dementia with Lewy bodies (DLB) is the second most common dementia, characterized by cognitive decline, hallucinations, and parkinsonism. DLB may bridge Alzheimer's and Parkinson's diseases, requiring specific treatments.
Area of Science:
- Neurology
- Geriatrics
- Pathology
Background:
- Dementia with Lewy bodies (DLB) is the second most common form of dementia, representing approximately 20% of cases.
- DLB is characterized by a combination of dementia, delirium, visual hallucinations, and parkinsonism.
- Associated symptoms include syncope, falls, sleep disorders, and depression.
Purpose of the Study:
- To describe the characteristics, diagnosis, and management of Dementia with Lewy bodies.
- To position DLB within the spectrum of neurodegenerative diseases, specifically between Alzheimer's disease and Parkinson's disease.
Main Methods:
- Diagnosis relies on clinical features and the exclusion of other potential causes of dementia.
- The study reviews existing literature on the pathophysiology, clinical presentation, and treatment of DLB.
Main Results:
- DLB pathology involves Lewy bodies and amyloid plaques, with neurotransmitter deficiencies (acetylcholine and dopamine).
- Cholinesterase inhibitors show greater efficacy in DLB than in Alzheimer's disease.
- Patients with DLB respond poorly to antiparkinsonian medications, and anticholinergic drugs should be avoided.
Conclusions:
- Dementia with Lewy bodies is a distinct clinical entity with unique diagnostic and therapeutic considerations.
- Management requires individualized approaches, including behavioral, environmental, and pharmacologic strategies.
- Certain medications, like traditional antipsychotics, can be particularly dangerous for DLB patients, increasing mortality risk.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...